Inactivation of p16 by CpG hypermethylation in renal cell carcinoma

Urologic Oncology: Seminars and Original Investigations

Volumn 26, Issue 3, 2008, Pages 239-245

  Vidaurreta, Marta ^a   Maestro, M Luisa ^a   Sanz Casla, M Teresa ^a   Maestro, Carmen ^b   Rafael, Sara ^a   Veganzones, Silvia ^a   Moreno, Jesus ^a   Blanco, Julia ^a   Silmi, Angel ^a   Arroyo, Manuel ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cancer; Kidney; p16 promoter methylation; p16 protein; Prognosis

Indexed keywords

ADULT; ARTICLE; CPG ISLAND; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; METHYLATION; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 42949122614     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.01.018     Document Type: Article

References (35)

1. Liggett W.H., and Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16 (1998) 1197-1206
2. Serrano M., Hannon G.J., and Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366 (1993) 704-707
3. Nobori P., Miura K., Wu D.J., et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368 (1994) 753-756
4. Herman J.G., Merlo A., Mao L., et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55 (1995) 4525-4530
5. Bird A. The essentials of DNA methylation. Cell 70 (1992) 5-8
6. Merlo A., Herman J.G., Mao L., et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS-1 in human cancers. Nature Med 1 (1995) 686-692
7. Moch H., Presti J.C., Sauter G., et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell cancer. Cancer Res 56 (1996) 27-30
8. Schullerus D., Herbers J., Chudek J., et al. Loss of heterozygosity at chromosomes 8p, 9p, and 14p is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol 183 (1997) 151-155
9. Cairns P., Tokino K., Eby Y., et al. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 55 (1995) 224-227
10. Kinoshita H., Yamada H., Ogawa O., et al. Contribution of chromosome 9p21-22 deletion to the progression of human renal cell carcinoma. Jpn J Cancer Res 86 (1995) 795-799
11. Störkel S., Eble J.N., Adlakha K., et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 987-989
12. Fuhrman S.A., Lasky L.C., and Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6 (1982) 655-663
13. Guinan P., Sobin L.H., Algaba F., et al., TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 992-993
14. Gerardts J., Hruban R.H., Schutte M., et al. Immunohistochemical p16INK4a analysis of archival tumors with deletion, hypermethylation, or mutation of CDKN2/MTS1 gene. A comparison of four commercial antibodies. Appl Immunohistochem Mol Morphol 8 (2000) 71-79
15. Thrash-Bingham C.A., Salazar H., Freed J., et al. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res 55 (1995) 6189-6195
16. Kashiwabara K., Oyama T., Sano T., et al. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers. Int J Cancer 79 (1998) 215-220
17. Herman J.G., Latif F., Weng Y., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91 (1994) 9700-9704
18. Sakai T., Toguchida J., Ohtani N., et al. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48 (1991) 880-888
19. Esteller M., Corn P.G., Baylin S.B., et al. A gene hypermethylation profile of human cancer. Cancer Res 61 (2001) 3225-3229
20. INK4α genes in renal cell carcinomas. Jpn J Cancer Res 92 (2001) 1293-1299
21. INK4a by CpG hypermethylation is not a frequent event in colorectal cancer. J Surg Oncol 84 (2003) 143-150
22. INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 21 (2003) 1688-1697
23. Qin Y., Liu J., Li B., et al. Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis. World J Gastroenterol 10 (2004) 1276-1280
24. INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C. Gut 48 (2001) 372-377
25. Kinoshita H., Yamada H., Ogawa O., et al. Contribution of chromosome 9p21-22 deletion to the progression of human renal cell carcinoma. Jpn J Cancer Res 86 (1995) 795-799
26. Okamoto A., Demetrick D.J., Spillare E.A., et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91 (1994) 11045-11049
27. Junker K., Weirich G., Amin M.B., et al. Genetic subtyping of renal cell carcinoma by comparative genomic hybridization. Recent Results Cancer Res 162 (2003) 169-175
28. INK4a in anatomic and gender-specific subtypes of sporadic colorectal cancer. Cancer Epidemiol Biomarkers Prev 8 (1999) 501-506
29. Lengauer C., Kinzler K., and Vogelstein B. Genetic instability in colorectal cancers. Nature 386 (1997) 623-627
30. Toyota M., Ohe-Toyota M., Ahuja N., et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci USA 97 (2000) 710-715
31. Hawkins N., Norrie M., Cheong K., et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 122 (2002) 1376-1387
32. Kane M.F., Loda M., Gaida G.M., et al. Methylation of hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 57 (1997) 808-811
33. Ward R.L., Cheong K., Ku S.L., et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. J Clin Oncol 21 (2003) 3729-3736
34. Gryfe R., Kim H., Hsieh E.T., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342 (2000) 69-77
35. Wright C.M., Dent O.F., Barker M., et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 87 (2000) 1197-1202